EGFR and neoplasm: GBM still remains a challenge because these tumors are resistant to anti-EGFR therapy, always relapse (Stupp et al., 2009) and recurrent tumors are less sensitive to chemotherapy than the primary tumor, developing novel anti-EGFR agents remains urgent (Campos et al., 2016; Eskilsson et al., 2018).